Chishima Real Estate, M3, Miraca, Nippon Life, POC Clinical Research, Reprocell, Toho Holdings and Zenoaq have all scored exits after the cell therapy provider went public.

Dell Technologies Capital and Hearst Ventures are backing a PIPE investment as the SK Holdings, Avis Budget, NTT Docomo and Delphi-backed vehicle data provider looks to list on Nasdaq.

NAB's UBank subsidiary has agreed to buy one of its portfolio companies, banking app developer 86400, at a valuation of approximately $207m.

The GV-backed stem cell drug developer has set terms for an initial public offering that would raise between $300m and $345m.

The Tencent and WMG-backed game development platform operator, valued at $29.5bn as of last month. is pausing its direct listing plans due to regulatory scrutiny.

Volpara Health has acquired CRA Health, a spinout of Havard Medical School’s teaching hospital Massachusetts General Hospital.

The New York Stock Exchange, BBVA, Docomo Capital and USAA-backed crypto trading platform operator is changing tack from an IPO to a direct listing.

Elron and Intel have exited the networking security technology developer in a $50m acquisition by Rapid7 following some $12m of funding.

Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.

The Tencent and Baidu-backed short-form video platform developer priced an offering valuing it at about $61bn at the top of its range.